scholarly journals Evaluating the granzyme production from CD8 T cells and NK1.1 natural killer cell after treating by the combination of Momordica charantia and Averrhoa bilimbi extract in STZ induced mice

2021 ◽  
Author(s):  
Wira Eka Putra ◽  
Muhaimin Rifa'i ◽  
Sri Rahayu Lestari ◽  
Hendra Susanto ◽  
Abdul Gofur
Keyword(s):  
T Cells ◽  
Natural Killer Cell ◽  
Natural Killer ◽  
Cd8 T Cells ◽  
Killer Cell ◽  
Momordica Charantia

Regulation of antiviral CD8+ T cells by inhibitory natural killer cell receptors

2003 ◽  
Vol 5 (2) ◽  
pp. 169-177 ◽  
Author(s):  
Anthony M. Byers ◽  
Christopher C. Kemball ◽  
Nicolas P. Andrews ◽  
Aron E. Lukacher
Keyword(s):  
T Cells ◽  
Natural Killer Cell ◽  
Natural Killer ◽  
Cd8 T Cells ◽  
Killer Cell ◽  
Cell Receptors ◽  
Natural Killer Cell Receptors

scholarly journals Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells

Immunology ◽  
2001 ◽  
Vol 103 (3) ◽  
pp. 281-290 ◽  
Author(s):  
Takashi Ohkawa ◽  
Shuhji Seki ◽  
Hiroshi Dobashi ◽  
Yuji Koike ◽  
Yoshiko Habu ◽  
...  
Keyword(s):  
T Cells ◽  
Natural Killer Cells ◽  
Natural Killer Cell ◽  
Natural Killer ◽  
Cd8 T Cells ◽  
Killer Cell ◽  
Killer Cells ◽  
Cell Markers

Comparing of pan-cancer tumor immune microenvironment.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15100-e15100
Author(s):  
Jiaan Ye ◽  
Longgang Cui ◽  
Xiaochen Zhao ◽  
Guanghui Lan
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
Natural Killer Cell ◽  
Natural Killer ◽  
Cancer Patients ◽  
Killer Cell ◽  
Immune Microenvironment ◽  
Hepatobiliary Cancer ◽  
Tumor Immune Microenvironment ◽  
Pan Cancer

e15100 Background: Cancer treatment has entered the era of immune checkpoint inhibitors (ICI), but different tumors have different responses to ICI drugs. For example, non-small cell lung cancer and melanoma have higher response rates to ICIs than colorectal cancer and liver cancer patients. Previous studies have shown that tumor immune microenvironment have a great impact on the efficacy of ICI. Methods: This study retrospectively included pan-cancer patient specimens, using multiple fluorescent labeling immunohistochemistry to explore the differences in the immune microenvironment of different tumors. Shapiro-Wilk was used for normality test, and ANOVA or Kruskal Wallis test was used according to the results. Two-sided P < 0.05 was considered a significant difference. Results: The study included 308 patients, including 119 (38.6%) NSCLC patients, 72 (23.4%) Colorectal cancer patients, 51 (16.6%) Hepatobiliary cancer patients and 66 (21.4%) Others types of cancer patients. Among them, there was 192 (62.3%) Male, and 116 (37.7%) Female, and the median age was 57 (50-66). The proportion of CD8+ T cells and natural killer cell in tumor was statistically different. The proportion of CD8+ T cells in NSCLC, Colorectal cancer, Hepatobiliary cancer and others was 2.16%, 1%, 1.77% and 2.63%, p < 0.01; the proportion of natural killer cell was 16.44 %, 4.91%, 5.58% and 3.29%, p < 0.01. Conclusions: Different tumor types have different immune microenvironments. These results may provide valuable clues for future ICI trail design.

Sign in / Sign up

Export Citation Format

Share Document